Targeting efficiency of nanoliposomes on atherosclerotic foam cells: polyethylene glycol-to-ligand ratio effects

References

• Ryan SM, Mantovani G, Wang X, et al. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv. 2008 Apr;5(4):371–383.
   PubMed Web of Science ®Google Scholar
• Howard MD, Jay M, Dziubla TD, et al. PEGylation of nanocarrier drug delivery systems: state of the art. J Biomed Nanotechnol. 2008;4:133–148. DOI:10.1166/jbn.2008.021
   Google Scholar
• Wong JY, Kuhl TL, Israelachvili JN, et al. Direct measurement of a tethered ligand-receptor interaction potential. Science. 1997 Feb 7;275(5301):820–822.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005 Feb;4(2):145–160.
   PubMed Web of Science ®Google Scholar
• Klibanov AL, Maruyama K, Torchilin VP, et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. Febs Lett. 1990 Jul 30;268(1):235–237.
   PubMed Web of Science ®Google Scholar
• Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomed. 2015;10:975–999.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol. 2010;197:3–53.
   PubMedGoogle Scholar
• Furusho Y, Miyata M, Matsuyama T, et al. Novel therapy for atherosclerosis using recombinant immunotoxin against folate receptor beta-expressing macrophages. J Am Heart Assoc. 2012 Aug;1(4):e003079.
   PubMed Web of Science ®Google Scholar
• Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013 Oct;13(10):709–721.
   PubMed Web of Science ®Google Scholar
• Wong YS, Czarny B, Venkatraman S. Precision nanomedicine in atherosclerosis therapy: how far are we from reality? Precis Nanomed. 2019 Jan 17;2:227–241.
   Google Scholar
• Hilgendorf I, Swirski FK. Folate receptor: a macrophage “achilles’ heel”? J Am Heart Assoc. 2012 Aug;1(4):e004036.
   PubMed Web of Science ®Google Scholar
• Xia W, Hilgenbrink AR, Matteson EL, et al. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood. 2009 Jan 8;113(2):438–446.
   PubMed Web of Science ®Google Scholar
• Varghese B, Vlashi E, Xia W, et al. Folate receptor-beta in activated macrophages: ligand binding and receptor recycling kinetics. Mol Pharm. 2014 Oct 6;11(10):3609–3616.
   PubMedGoogle Scholar
• Antohe F. Endothelial cells and macrophages, partners in atherosclerotic plaque progression. Arch Physiol Biochem. 2006 Oct-Dec;112(4–5):245–253.
   PubMedGoogle Scholar
• Antony AC. Folate receptors. Annu Rev Nutr. 1996;16:501–521.
   PubMed Web of Science ®Google Scholar
• Caracciolo G. Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines. Nanomedicine. 2015 Apr;11(3):543–557.
   PubMed Web of Science ®Google Scholar
• Reddy JA, Abburi C, Hofland H, et al. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther. 2002 Nov;9(22):1542–1550.
   PubMed Web of Science ®Google Scholar
• Johnstone SA, Masin D, Mayer L, et al. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta. 2001 Jul 2;1513(1):25–37.
   PubMed Web of Science ®Google Scholar
• Hironaka K, Inokuchi Y, Tozuka Y, et al. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J Control Release. 2009 Jun 19;136(3):247–253.
   PubMed Web of Science ®Google Scholar
• Lim HY, Lim SY, Tan CK, et al. Hyaluronan receptor LYVE-1-expressing macrophages maintain arterial tone through hyaluronan-mediated regulation of smooth muscle cell collagen. Immunity. 2018 Dec 18;49(6):1191.
   PubMed Web of Science ®Google Scholar
• Liu H, Li Z, Sun Y, et al. Synthesis of luminescent carbon dots with ultrahigh quantum yield and inherent folate receptor-positive cancer cell targetability. Sci Rep. 2018 Jan 18;8(1):1086.
   PubMedGoogle Scholar
• Gabrielson NP, Pack DW. Efficient polyethylenimine-mediated gene delivery proceeds via a caveolar pathway in HeLa cells. J Control Release. 2009 May 21;136(1):54–61.
   PubMed Web of Science ®Google Scholar
• Yanchao S, Shi W, Chen W, et al. Fluorescent carbon nanodots conjugated with folic acid for distinguishing folate-receptor-positive cancer cells from normal cells. J Mater Chem. 2012;25:12568–12573.
   Google Scholar
• Saul JM, Annapragada A, Natarajan JV, et al. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release. 2003 Sep 19;92(1–2):49–67.
   PubMed Web of Science ®Google Scholar
• Chonn A, Semple SC, Cullis PR. Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. Biochim Biophys Acta. 1991 Nov 18;1070(1):215–222.
   PubMed Web of Science ®Google Scholar
• Harvie P, Desormeaux A, Bergeron MC, et al. Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2ʹ,3ʹ-dideoxyinosine. Antimicrob Agents Chemother. 1996 Jan;40(1):225–229.
   PubMed Web of Science ®Google Scholar
• Hrkach J, Von Hoff D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012 Apr 4;4(128):128ra39.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Horowitz AT, Goren D, et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem. 1999 Mar-Apr;10(2):289–298.
   PubMed Web of Science ®Google Scholar
• Yamada A, Taniguchi Y, Kawano K, et al. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin Cancer Res. 2008 Dec 15;14(24):8161–8168.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid Interface Sci. 2001;6(1):66–77.
   Web of Science ®Google Scholar
• Hak S, Helgesen E, Hektoen HH, et al. The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in vivo by dual modality imaging. ACS Nano. 2012 Jun 26;6(6):5648–5658.
   PubMed Web of Science ®Google Scholar
• de Gennes PG. Polymers at an interface; a simplified view. Adv Colloid Interface Sci. 1987;27(3–4):189–209.
   Web of Science ®Google Scholar
• Pappalardo MD, Grasso D, La Rosa C. Phase behaviour of polymer-grafted DPPC membranes for drug delivery systems design. J Therm Anal Calorim. 2005;80(2):413–418.
   Web of Science ®Google Scholar
• Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49–60.
   PubMed Web of Science ®Google Scholar
• Fang Y, Xue J, Gao S, et al. Cleavable PEGylation: a strategy for overcoming the “PEG dilemma” in efficient drug delivery. Drug Deliv. 2017 Dec;24(sup1):22–32.
   PubMed Web of Science ®Google Scholar
• van der Valk FM, van Wijk DF, Lobatto ME, et al. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomedicine. 2015 Jul;11(5):1039–1046.
   PubMed Web of Science ®Google Scholar
• Chono S, Tauchi Y, Deguchi Y, et al. Efficient drug delivery to atherosclerotic lesions and the antiatherosclerotic effect by dexamethasone incorporated into liposomes in atherogenic mice. J Drug Target. 2005 May;13(4):267–276.
   PubMed Web of Science ®Google Scholar
• Schiener M, Hossann M, Viola JR, et al. Nanomedicine-based strategies for treatment of atherosclerosis. Trends Mol Med. 2014 May;20(5):271–281.
   PubMed Web of Science ®Google Scholar
• Chan CKW, Zhang L, Cheng CK, et al. Recent advances in managing atherosclerosis via nanomedicine. Small. 2018 Jan;14(4). doi:10.1002/smll.201702793.
   Web of Science ®Google Scholar
• Alaarg A, Senders ML, Varela-Moreira A, et al. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. J Control Release. 2017 Sep 28;262:47–57.
   PubMed Web of Science ®Google Scholar